Title
MK-2870-005
Host/Owner
Cancer Trials Ireland
Location(s)
Mater Misericordiae Hospital
Eligibility
Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
Full title
Randomized Study to Compare Efficacy and Safety of MK-2870 Monotherapy versus Treatment of Physician’s Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
Eligibility Criteria
Inclusion criteria:
- Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma.
- Has radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by BICR.
- Has received prior systemic, platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy, either separately or in combination, for endometrial carcinoma or carcinosarcoma.
- Has received up to 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma.
Exclusion criteria:
- Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas.
- Is a candidate for curative-intent surgery or curative-intent radiotherapy at the time of enrollment.
- Has Grade ≥2 peripheral neuropathy.
Closing date
TBC 2025
